
Currently out of the existing stock ratings of Kennen Mackay, 140 are a BUY (76.92%), 41 are a HOLD (22.53%), 1 are a SELL (0.55%).
Analyst Kennen Mackay, has had 65.82% of price targets met with an average potential upside of 31.91%, reached in 345 days on average. Previously, Kennen Mackay worked at RBC, CREDIT SUISSE, CITI.
Kennen Mackay has documented 352 price targets and ratings displayed on 33 stocks. The coverage was on Healthcare, Industrials, Consumer Defensive sectors.
Most recent stock forecast was given on PRTA, Prothena plc at 30-Sep-2024.
Analyst best performing recommendations are on ANAB (ANAPTYSBIO).
The best stock recommendation documented was for ANAB (ANAPTYSBIO) on 4/4/2018. The price target of $57.33 was fulfilled within 2 days with a profit of $5.57 (8.86%), with a performance score of 44.28.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Oct-2017
$18
$15.58 (643.80%)
$20
10 days ago
(12-Nov-2026)
0/21 (0%)
$15.71 (686.03%)
Buy Since 08-Nov-2022
$30
$27.58 (1139.67%)
$28
2 months 4 days ago
(18-Sep-2026)
1/8 (12.5%)
$24.43 (438.60%)
1
Buy Since 17-Mar-2026
$21
$18.58 (767.77%)
$22
3 months 8 days ago
(14-Aug-2026)
0/2 (0%)
$15.01 (250.58%)
Buy Since 29-Apr-2025
$17
$14.58 (602.48%)
$19
8 months 5 days ago
(17-Mar-2026)
0/4 (0%)
$12.24 (257.14%)
Buy Since 02-Jun-2025
$22
$19.58 (809.09%)
$20
8 months 13 days ago
(09-Mar-2026)
0/3 (0%)
$16.84 (326.36%)
Stocks Kennen Mackay covered previously. Scores are shown for active stocks only.
The record of these past calls is part of the data set at anachart.store.